Do We Have a Biocompatible Peritoneal Dialysis Fluid?


Objective: Cardiovascular disease remains the leading cause of morbidity and mortality in patients on maintenance dialysis. Diabetes mellitus, dyslipidemia, hypertension, inflammation and hyperhomocyteinemia are major cardiovascular risk factors. Aim: to evaluate the effects of Icodextrin and amino acid peritoneal dialysis fluid (AAPDF) on these major cardiovascular risk factors looking for a more biocompatible PDF formula. Methods: 24 adult stable peritoneal dialysis patients were included in the study. 12 patients received 2L Icodextrin and other 12 patients received 2L AAPDF in their dialysis prescription for 8 weeks. Results: Icodextrin decreased fasting plasma glucose (p < 0.001), LDL-C (p = 0.03), SBP (p < 0.01), DBP (p < 0.05) and plasma homocysteine (p = 0.002), and increased HDL-C (p = 0.009), CRP (p = 0.035) and fibrinogen (p = 0.009). AAPDF did not affect fasting plasma glucose, LDL-C, HDL-C, CRP and fibrinogen but increased serum albumin (p = 0.03), SBP (p < 0.01), DBP (p < 0.05) and PHcy (p = 0.03). Conclusions: A biocompatible PDF should provide not only adequate dialysis and ultrafiltration but should also improve nutritional and metabolic status, blood pressure control and reduce inflammation and plasma homocyteine.

Share and Cite:

S. Hassan, B. Kristal, K. Khazim, F. Hassan, D. Hassan and K. Hassan, "Do We Have a Biocompatible Peritoneal Dialysis Fluid?," Open Journal of Nephrology, Vol. 2 No. 3, 2012, pp. 29-34. doi: 10.4236/ojneph.2012.23005.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] [1] P. S. Parfrey and J. D. Harnett, “Long Term Cardiac Morbidity and Mortality during Dialysis Therapy,” Advanced Nephrology, Vol. 23, 1994, pp. 311-330.
[2] S. H. Park, P. Stenvinkel and B. Lindholm, “Cardiovascular Biomarkers in Chronic Kidney Disease,” Journal of Renal Nutrition, Vol. 22, No. 1, 2012, pp. 120-127. doi:10.1053/j.jrn.2011.10.021
[3] A. H. Mitwalli, A. A. Alam, J. S. Al Wakeel and A. C. Isnani, “Dyslipidemia in Dialysis Patients,” Saudi Journal of Kidney Disease and Transplantation, Vol. 22, No. 4, 2011, pp. 689-694.
[4] L. M. Ortega and B. J. Materson, “Hypertension in Peritoneal Dialysis Patients: Epidemiology, Pathogenesis, and Treatment,” Journal of the American Society of Hypertension, Vol. 5, No. 3, 2011, pp. 128-136. doi:10.1016/j.jash.2011.02.004
[5] M. Moriishi and H. Kawanishi, “Icodextrin and Intraperitoneal Inflammation,” Peritoneal Dialysis International, Vol. 28, Suppl. 3, 2008, pp. S96-S100.
[6] T. Huang, G. Yuan, Z. Zhang, Z. Zou and D. Li, “Cardiovascular Pathogenesis in Hyperhomocysteinemia,” Asia Pacific Journal of Clinical Nutrition, Vol. 17, No. 1, 2008, pp. 8-16.
[7] C. van Guldener and F. Stam, “Stehouwer CDA. Homo- cysteine Metabolism in Renal Failure,” Kidney International, Vol. 59, Suppl. 78, 2001, pp. S234-S237. doi:10.1046/j.1523-1755.2001.07859.x
[8] M. M. Sagheb, M. A. Ostovan, Z. Sohrabi, E. Atabati, G. A. Raisjalai and J. Roozbeh, “Hyperhomocysteinemia and Cardiovascular Risks in Hemodialysis Patients,” Saudi Journal of Kidney Diseases and Transplantation, Vol. 21, No. 5, 2010, pp. 863-866.
[9] L. A. Cooker, C. J. Holmes and C. M. Hoff, “Biocom- patibility of Icodextrin,” Kidney International, Vol. 62, Suppl. 81, 2002, pp. S34-S45. doi:10.1046/j.1523-1755.62.s81.6.x
[10] M. Canbakan and G. M. Sahin, “Icodextrine and Insulin Resistance in Continuous Ambulatory Peritoneal Dialysis Patients,” Renal Failure, Vol. 29, No. 3, 2007, pp. 289-293. doi:10.1080/08860220601166271
[11] T. A. Martikainen, A. M. Teppo, C. Gr?nhagen-Riska and A. V. Ekstrand, “Glucose-Free Dialysis Solutions: In- ductors of Inflammation or Preservers of Peritoneal Membrane?” Peritoneal Dialysis International, Vol. 25, No. 5, 2005, pp. 453-460.
[12] W. Lin, Y. C. Chen, M. S. Wu, H. J. Hsu, C. Y. Sun, Y. K.Lin and I. W. Wu, “Icodextrin Dialysate Improves Nutritional and Inflammatory Profiles in Peritoneal Dialysis Patients,” Renal Failure, Vol. 31, No. 2, 2009, pp. 98-105. doi:10.1080/08860220802595500
[13] F. K. Li, L. Y.Chan , J. C. Woo, et al., “A 3-Year, Prospective, Randomized, Controlled, Study on Amino Acid Dialysate in Patients on CAPD,” American Journal of Kidney Diseases, Vol. 42, No. 1, 2003, pp. 173-183. doi:10.1016/S0272-6386(03)00421-9
[14] A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers and D. Roth, “A More Accurate Method to Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation, Modification of Diet in Renal Disease Study Group,” Annals of Internal Medicine, Vol. 130, No. 6, 1999, pp. 461-470.
[15] Z. J. Twardowski, “Clinical Value of Standardized Equilibration Tests in CAPD Patients,” Blood Purification, Vol. 7, No. 2-3, 1989, pp. 95-108. doi:10.1159/000169582
[16] G. Amici, S. Mastrosimone, G. Da Rin, C. Bocci and A. Bonadonna, “Clinical Validation of PD Adequest Software: Modeling Error Assessment,” Peritoneal Dialysis International, Vol. 18, No. 3, 1998, pp. 317-321.
[17] H. Ha, M. R. Yu, H. N. Choi, M. K. Cha, H. S. Kang, M. H. Kim and H. B. Lee, “Effects of Conventional and New Peritoneal Dialysis Solutions on Human Peritoneal Mesothelial Cell Viability and Proliferation,” Peritoneal Di- alysis International, Vol. 20, Suppl. 5, 2000, pp. S10-S18.
[18] R. T. Krediet, M. M. Zweers, A. C. vander Wal and D. J. Struijk, “Neoangiogenesis in the Peritoneal Membrane,” Peritoneal Dialysis International, Vol. 20, Suppl. 2, 2000, pp. S19-S25.
[19] J. Delarue and C. Maingourd, “Acute Metabolic Effects of Dialysis Fluids during CAPD,” American Journal of Kidney Diseases, Vol. 37, Suppl. 2, 2001, pp. S103-S107. doi:10.1053/ajkd.2001.20762
[20] N. Posthuma, P. M. ter Wee, A. J. Donker, P. L. Oe, E. M. Peers and H. A. Verbrugh, “Assesement of the Effectiveness, Safety, and Biocompatibility of Icodextrin in Automated Peritoneal Dialysis. The Dextrin in APD in Amsterdam (DIANA) Group,” Peritoneal Dialysis International, Vol. 20, Suppl. 2, 2000, pp. S106-S113.
[21] T. W. Kao, H. F. Chuang, K. Y. Hung, K. D. Wu and T. J. Tsai, “Rate of Decline of Residual Renal Function is Associated with All-Cause Mortality and Technique Failure in Patients on Long-Term Peritoneal Dialysis,” Nephrology Dialysis Transplantation, Vol. 24, No. 9, 2009, pp. 2909-2914. doi:10.1093/ndt/gfp056
[22] S. Kim, J. Oh, S. Kim, W. Chung, C. Ahn, S. G. Kim and K. H. Oh, “Benefits of Biocompatible PD Fluid for Preservation of Residual Renal Function in Incident CAPD Patients: A 1-Year Study,” Nephrology Dialysis Trans- plantation, Vol. 24, No. 9, 2009, pp. 2899-2908. doi:10.1093/ndt/gfp054
[23] S. J. Bredie, F. H. Bosch, P. N. Demacker, A. F. Stalen- hoef and R. van Leusen, “Effects of Peritoneal Dialysis with an Overnight Icodextrin Dwell on Parameters of Glucose and Lipid Metabolism,” Peritoneal Dialysis International, Vol. 21, No. 3, 2001, pp. 275-281.
[24] C. Van Guldener, “Why is Homocysteine Elevated in Renal Failure and What Can Be Expected from Homo-cysteine-Lowering?” Peritoneal Dialysis International, Vol. 21, No. 5, 2006, pp. 1161-1166. doi:10.1093/ndt/gfl044
[25] A. Czupryniak, M. Nowicki, G. Chwatko, A. Jander, E. Bald, “Peritoneal Clearance of Homocysteine with Icodextrin or Standard Glucose Solution Exchange,” Nephrology (Carlton), Vol. 10, No. 6, 2005, pp. 571-575.
[26] H. F. Brulez, C. van Guldener, A. J.Donker , P. M. ter Wee, “The Impact of an Amino Acid-Based Peritoneal Dialysis Fluid on Plasma Total Homocysteine Levels, Lipid Profile and Body Fat Mass,” Nephrology Dialysis Transplantation, Vol. 14, No. 1, 1999, pp. 154-159. doi:10.1093/ndt/14.1.154
[27] S. Y. Yang, J. W. Huang, K. Y. Shih, et al., “Factors Associated with Increased Plasma Homocysteine in Patients Using an Amino Acid Peritoneal Dialysis Fluid,” Nephrology Dialysis Transplantation, Vol. 20, No. 1, 2005, pp. 161-166. doi:10.1093/ndt/gfh554
[28] S. Haas, C. P. Schmitt, K. Arbeiter, K. E. Bonzel, M. Fischbach, U. John, A. K. Pieper, T. P. Schaub, J. Passlick-Deetjen and O. Mehls, “Schaefer FImproved Acidosis Correction and Recovery of Mesothelial Cell Mass with NeutralpH Bicarbonate Dialysis Solution among Children Undergoing Automated Peritoneal Dialysis,” Journal of the American Society of Hypertension, Vol. 14, No. 10, 2003, pp. 2632-2638. doi:10.1097/01.ASN.0000086475.83211.DF
[29] D. Ducloux, L. Heuze-Lecornu, R. Gibey, C. Bresson-Vautrin, P. Vautrin and J. M. Chalopin, “Dialysis Adequacy and Homocyst(e)ine Concentrations in Peritoneal Dialysis Patients,” Nephrology Dialysis Transplantation, Vol. 14, No. 3, 1999, pp. 728-731. doi:10.1093/ndt/14.3.728
[30] A. Vychytil, M. Fodinger, M. Papagiannopoulos, et al., “Peritoneal Elimination of Homocysteine Moieties in Continuous Ambulatory Peritoneal Dialysis Patients,” Kidney International, Vol. 55, No. 5, 1999, pp. 2054-2061. doi:10.1046/j.1523-1755.1999.00437.x

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.